SCHEMBL6744834

SCHEMBL6744834

CC(=O)c1ccc(Cl)c(N(Cc2ccccc2)S(C)(=O)=O)c1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.56
MEN1 O00255 10/20 0.56
ALDH1A1 P00352 2/20 0.49
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 1/20 0.46
POLB P06746 1/20 0.46
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7529540 0.88 MEN1 (0.52) KMT2AMEN1ALDH1A1NPSR1POLB
SCHEMBL7242360 0.86 MEN1 (0.51) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL6744892 0.85 KMT2A (0.56) KMT2AMEN1ALDH1A1NPSR1MAPT
SCHEMBL6743658 0.81 KMT2A (0.53) KMT2AMEN1ALDH1A1NPSR1MAPT
SCHEMBL7615925 0.81 PPARG (0.49) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL7618948 0.81 PPARG (0.49) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL963777 0.81 MEN1 (0.52) KMT2AMEN1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL9689759 0.78 MEN1 (0.70) KMT2AMEN1ALDH1A1NPSR1MAPT
SCHEMBL6744201 0.77 KMT2A (0.69) KMT2AMEN1ALDH1A1NPSR1MAPT
SCHEMBL27555237 0.77 MEN1 (0.44) KMT2AMEN1ALDH1A1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6696573-B1 SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY ASAHI KASEI KABUSHIKI KAISHA (JP) 2004-02-24 US disclosed
US-20030225289-A1 Process for the preparation of tricyclic amino alcohol derivatives ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-12-04 US disclosed
US-20030045727-A1 Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-03-06 US disclosed
US-6495701-B1 THE PRESENT INVENTION IS DIRECTED TO PROCESSES FOR THE PREPARATION OF A COMPOUND USEFUL FOR TREATING DIABETES, OBESITY, HYPERLIPIDEMIA AND THE LIKE, ASAHI KASEI KABUSHIKI KAISHA (JP) 2002-12-17 US disclosed
EP-1254885-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS Asahi Kasei Kabushiki Kaisha (JP) 2002-11-06 EP disclosed
EP-1209150-A1 PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES Asahi Kasei Kabushiki Kaisha (JP) 2002-05-29 EP disclosed
EP-1195371-A1 PROCESS FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES Asahi Kasei Kabushiki Kaisha (JP) 2002-04-10 EP disclosed
EP-1174425-A1 NOVEL METHOD FOR MANUFACTURING TRICYCLIC AMINO ALCOHOL DERIVATIVES Asahi Kasei Kabushiki Kaisha (JP) 2002-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225289-A1 Process for the preparation of tricyclic amino alcohol derivatives ADH1A, ADH1C, OXER1 KMT2A 938/4885MEN1 3399/4885ALDH1A1 80/4885
US-20030045727-A1 Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups ADH1A, ADH5, ADH1C KMT2A 2277/4885MEN1 3345/4885ALDH1A1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.